Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors

Complete title: SC-4014 A Phase 1, Open-label, Dose Escalation Study of MGA271 in Pediatric Patients with B7-H3-Expressing Relapsed or Refractory Solid Tumors

Research Study Number SC-4014
Principal Investigator Julie Park, MD
Phase I

Research Study Description

This study is a Phase 1, open-label, dose escalation and cohort expansion trial designed to characterize the safety, tolerability, PK, PD, immunogenicity and preliminary antitumor activity of enoblituzumab administered IV on a weekly schedule for up to 96 doses (approximately 2 years) in children and young adults with B7-H3-expressing relapsed or refractory malignant solid tumors.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number SC-4014
Contact Kim Starr, CCRP
Telephone 206/884-7274

Keywords: Kidney Cancer; Pediatric Cancers, Miscellaneous; Neuroblastoma; Neuroectodermal Tumors, Primitive (PNET); Solid Tumors; Wilms' Tumor; Neoplasms, Germ Cell and Embryonal; Urogenital Neoplasms; Urologic Neoplasms; Neuroectodermal Tumors; Rhabdomyosarcoma; Sarcoma, Ewing; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue; Neoplasms, Neuroepithelial; Osteosarcoma; Neoplasms, Connective and Soft Tissue; Neoplasms, Bone Tissue; Myosarcoma; Neoplasms, Muscle Tissue; Neoplasms, Complex and Mixed; Genetic Diseases, Inborn; Desmoplastic Small Round Cell Tumor

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials